ERBB2 and breast cancer: Plasma from BC patients was used to detect HER2 gene amplifications and mutations in plasma of BC patients, demonstrating that the detection of mutations in other HER2 signaling-related genes such as PIK3CA, may predict resistance to anti-HER2 therapy.